Provides updates on BioNTech’s strategy to scale and deploy AI-capabilities across the immunotherapy pipelineHighlights InstaDeep’s new near ...

BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...

Arcturus Therapeutics ARCT and partner CSL Seqirus, a renowned vaccine company, together reported encouraging results from a ...

The newest update to the COVID-19 vaccine reached pharmacies as infections in Indiana began to rise. Members of our audience ...

The BioNTech SE ADR BNTX inched 0.49% higher to $118.22 Friday, on what proved to be an all-around mixed trading session for ...

BioNTech BNTX has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from ...

AbbVie Humira, Pfizer/BioNTech COVID-19 shot may not make top 10 pharma drugs in 2024, with Novo Nordisk Ozempic and ...

Health Canada approved Pfizer-BioNTech’s updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...

Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that Health Canada has authorized the KP.2 ...

Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European ...

BioNTech SE ADR closed $10.99 short of its 52-week high ($115.99), which the company reached on September 14th.